Literature DB >> 1177986

Cyproheptadine-induced remission of Cushing's disease.

D T Krieger, L Amorosa, F Linick.   

Abstract

Experimental evidence suggests a central-nervous-system origin of Cushing's disease and a role for serotonin in the regulation of ACTH release. The efficacy of cyproheptadine therapy, therefore, was studied in three patients with such disease. Administration of 24 mg daily over a period of three to six months was associated with prompt and sustained clinical and laboratory remission. Lessening of the physical manifestations of hypercorticism occurred, together with marked improvement in muscular weakness. Urinary corticosteroid excretion and cortisol secretory rate returned to normal. The urinary corticosteroid response to dexamethasone (2 mg per day) became normal; a paradoxical increase followed 8 mg per day. Abnormal circadian periodicity of plasma cortisol concentrations persisted. Return of normal amounts of Stage III to IV sleep occurred in the one patient so studied, who previously had markedly decreased periods of these stages. Discontinuance of therapy in one patient was associated with return of laboratory evidence of hypercorticism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1177986     DOI: 10.1056/NEJM197510302931802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

1.  Positive rate-sensitive corticosteroid feedback mechanism of ACTH secretion in Cushing's disease.

Authors:  H L Fehm; K H Voigt; G Kummer; E F Pfeiffer
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

2.  Pituitary-dependent Cushing's disease.

Authors:  S P Deacon
Journal:  Br Med J       Date:  1977-05-28

3.  Internal medicine-epitomes of progress: pituitary cushing syndrome: new options for treatment.

Authors:  E M Gold
Journal:  West J Med       Date:  1978-07

Review 4.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

5.  Inhibition of stress-induced hyperprolactinaemia.

Authors:  B Corenblum; M Whitaker
Journal:  Br Med J       Date:  1977-11-19

6.  Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.

Authors:  A B Atkinson; A L Kennedy; B Sheridan
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

7.  Diagnosis, treatment and postoperative results of Cushing's disease.

Authors:  N Kageyama; A Kuwayama; T Takahashi; M Negoro; K Ichihara
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

Review 8.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

9.  Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion.

Authors:  P Loli; M E Berselli; F Frascatani; F Muratori; M Tagliaferri
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

10.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

Authors:  S A Fine; L A Frohman
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.